Portal de Periódicos da CAPES

Revolutionizing Alzheimer's disease and clinical trials through biomarkers

2015; Elsevier BV; Volume: 1; Issue: 4 Linguagem: Inglês

10.1016/j.dadm.2015.09.001

2352-8729

Niklas Mattsson, María C. Carrillo, Robert A. Dean, Michael D. Devous, Tania Nikolcheva, Pedro Pesini, Hugh Salter, William Z. Potter, Reisa Sperling, Randall J. Bateman, Lisa J. Bain, Enchi Liu,

S100 Proteins and Annexins

Abstract The Alzheimer's Association's Research Roundtable met in May 2014 to explore recent progress in developing biomarkers to improve understanding of disease pathogenesis and expedite drug development. Although existing biomarkers have proved extremely useful for enrichment of subjects in clinical trials, there is a clear need to develop novel biomarkers that are minimally invasive and that more broadly characterize underlying pathogenic mechanisms, including neurodegeneration, neuroinflammation, and synaptic dysfunction. These may include blood‐based assays and new neuropsychological testing protocols, as well as novel ligands for positron emission tomography imaging, and advanced magnetic resonance imaging methodologies. In addition, there is a need for biomarkers that can serve as theragnostic markers of response to treatment. Standardization remains a challenge, although international consortia have made substantial progress in this area and provide lessons for future standardization efforts.